Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis

Ali Syed Arbab, Victor Frenkel, Sunil D. Pandit, Stasia A. Anderson, Gene T. Yocum, Monica Bur, Hanh M. Khuu, Elizabeth J. Read, Joseph A. Frank

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

AC133 cells, a subpopulation of CD34+ hematopoietic stem cells, can transform into endothelial cells that may integrate into the neovasculature of tumors or ischemic tissue. Most current imaging modalities do not allow monitoring of early migration and incorporation of endothelial progenitor cells (EPCs) into tumor neovasculature. The goals of this study were to use magnetic resonance imaging (MRI) to track the migration and incorporation of intravenously injected, magnetically labeled EPCs into the blood vessels in a rapidly growing flank tumor model and to determine whether the pattern of EPC incorporation is related to the time of injection or tumor size. Materials and Methods: EPCs labeled with ferumoxide-protamine sulfate (FePro) complexes were injected into mice bearing xenografted glioma, and MRI was obtained at different stages of tumor development and size. Results: Migration and incorporation of labeled EPCs into tumor neovasculature were detected as low signal intensity on MRI at the tumor periphery as early as 3 days after EPC administration in preformed tumors. However, low signal intensities were not observed in tumors implanted at the time of EPC administration until tumor size reached 1 cm at 12 to 14 days. Prussian blue staining showed iron-positive cells at the sites corresponding to low signal intensity on MRI. Confocal microcopy showed incorporation into the neovasculature, and immunohistochemistry clearly demonstrated the transformation of the administered EPCs into endothelial cells. Conclusion: MRI demonstrated the incorporation of FePro-labeled human CD34 +/AC133+ EPCs into the neovasculature of implanted flank tumors.

Original languageEnglish (US)
Pages (from-to)671-678
Number of pages8
JournalStem Cells
Volume24
Issue number3
DOIs
StatePublished - Jan 1 2006

Fingerprint

Confocal Microscopy
Magnetic Resonance Imaging
Neoplasms
Protamines
Endothelial Progenitor Cells
Endothelial Cells
Hematopoietic Stem Cells
Glioma
Blood Vessels
Iron
Immunohistochemistry
Staining and Labeling
Injections

Keywords

  • Ferumoxides
  • Hematopoietic stem cells
  • Magnetic resonance imaging
  • Neovasculature
  • Protamine sulfate
  • Quantum dots
  • Vasculogenesis

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. / Arbab, Ali Syed; Frenkel, Victor; Pandit, Sunil D.; Anderson, Stasia A.; Yocum, Gene T.; Bur, Monica; Khuu, Hanh M.; Read, Elizabeth J.; Frank, Joseph A.

In: Stem Cells, Vol. 24, No. 3, 01.01.2006, p. 671-678.

Research output: Contribution to journalArticle

Arbab, Ali Syed ; Frenkel, Victor ; Pandit, Sunil D. ; Anderson, Stasia A. ; Yocum, Gene T. ; Bur, Monica ; Khuu, Hanh M. ; Read, Elizabeth J. ; Frank, Joseph A. / Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. In: Stem Cells. 2006 ; Vol. 24, No. 3. pp. 671-678.
@article{767bc7e28c364dfd943ca5387c8a2a06,
title = "Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis",
abstract = "AC133 cells, a subpopulation of CD34+ hematopoietic stem cells, can transform into endothelial cells that may integrate into the neovasculature of tumors or ischemic tissue. Most current imaging modalities do not allow monitoring of early migration and incorporation of endothelial progenitor cells (EPCs) into tumor neovasculature. The goals of this study were to use magnetic resonance imaging (MRI) to track the migration and incorporation of intravenously injected, magnetically labeled EPCs into the blood vessels in a rapidly growing flank tumor model and to determine whether the pattern of EPC incorporation is related to the time of injection or tumor size. Materials and Methods: EPCs labeled with ferumoxide-protamine sulfate (FePro) complexes were injected into mice bearing xenografted glioma, and MRI was obtained at different stages of tumor development and size. Results: Migration and incorporation of labeled EPCs into tumor neovasculature were detected as low signal intensity on MRI at the tumor periphery as early as 3 days after EPC administration in preformed tumors. However, low signal intensities were not observed in tumors implanted at the time of EPC administration until tumor size reached 1 cm at 12 to 14 days. Prussian blue staining showed iron-positive cells at the sites corresponding to low signal intensity on MRI. Confocal microcopy showed incorporation into the neovasculature, and immunohistochemistry clearly demonstrated the transformation of the administered EPCs into endothelial cells. Conclusion: MRI demonstrated the incorporation of FePro-labeled human CD34 +/AC133+ EPCs into the neovasculature of implanted flank tumors.",
keywords = "Ferumoxides, Hematopoietic stem cells, Magnetic resonance imaging, Neovasculature, Protamine sulfate, Quantum dots, Vasculogenesis",
author = "Arbab, {Ali Syed} and Victor Frenkel and Pandit, {Sunil D.} and Anderson, {Stasia A.} and Yocum, {Gene T.} and Monica Bur and Khuu, {Hanh M.} and Read, {Elizabeth J.} and Frank, {Joseph A.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1634/stemcells.2005-0017",
language = "English (US)",
volume = "24",
pages = "671--678",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis

AU - Arbab, Ali Syed

AU - Frenkel, Victor

AU - Pandit, Sunil D.

AU - Anderson, Stasia A.

AU - Yocum, Gene T.

AU - Bur, Monica

AU - Khuu, Hanh M.

AU - Read, Elizabeth J.

AU - Frank, Joseph A.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - AC133 cells, a subpopulation of CD34+ hematopoietic stem cells, can transform into endothelial cells that may integrate into the neovasculature of tumors or ischemic tissue. Most current imaging modalities do not allow monitoring of early migration and incorporation of endothelial progenitor cells (EPCs) into tumor neovasculature. The goals of this study were to use magnetic resonance imaging (MRI) to track the migration and incorporation of intravenously injected, magnetically labeled EPCs into the blood vessels in a rapidly growing flank tumor model and to determine whether the pattern of EPC incorporation is related to the time of injection or tumor size. Materials and Methods: EPCs labeled with ferumoxide-protamine sulfate (FePro) complexes were injected into mice bearing xenografted glioma, and MRI was obtained at different stages of tumor development and size. Results: Migration and incorporation of labeled EPCs into tumor neovasculature were detected as low signal intensity on MRI at the tumor periphery as early as 3 days after EPC administration in preformed tumors. However, low signal intensities were not observed in tumors implanted at the time of EPC administration until tumor size reached 1 cm at 12 to 14 days. Prussian blue staining showed iron-positive cells at the sites corresponding to low signal intensity on MRI. Confocal microcopy showed incorporation into the neovasculature, and immunohistochemistry clearly demonstrated the transformation of the administered EPCs into endothelial cells. Conclusion: MRI demonstrated the incorporation of FePro-labeled human CD34 +/AC133+ EPCs into the neovasculature of implanted flank tumors.

AB - AC133 cells, a subpopulation of CD34+ hematopoietic stem cells, can transform into endothelial cells that may integrate into the neovasculature of tumors or ischemic tissue. Most current imaging modalities do not allow monitoring of early migration and incorporation of endothelial progenitor cells (EPCs) into tumor neovasculature. The goals of this study were to use magnetic resonance imaging (MRI) to track the migration and incorporation of intravenously injected, magnetically labeled EPCs into the blood vessels in a rapidly growing flank tumor model and to determine whether the pattern of EPC incorporation is related to the time of injection or tumor size. Materials and Methods: EPCs labeled with ferumoxide-protamine sulfate (FePro) complexes were injected into mice bearing xenografted glioma, and MRI was obtained at different stages of tumor development and size. Results: Migration and incorporation of labeled EPCs into tumor neovasculature were detected as low signal intensity on MRI at the tumor periphery as early as 3 days after EPC administration in preformed tumors. However, low signal intensities were not observed in tumors implanted at the time of EPC administration until tumor size reached 1 cm at 12 to 14 days. Prussian blue staining showed iron-positive cells at the sites corresponding to low signal intensity on MRI. Confocal microcopy showed incorporation into the neovasculature, and immunohistochemistry clearly demonstrated the transformation of the administered EPCs into endothelial cells. Conclusion: MRI demonstrated the incorporation of FePro-labeled human CD34 +/AC133+ EPCs into the neovasculature of implanted flank tumors.

KW - Ferumoxides

KW - Hematopoietic stem cells

KW - Magnetic resonance imaging

KW - Neovasculature

KW - Protamine sulfate

KW - Quantum dots

KW - Vasculogenesis

UR - http://www.scopus.com/inward/record.url?scp=33646752857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646752857&partnerID=8YFLogxK

U2 - 10.1634/stemcells.2005-0017

DO - 10.1634/stemcells.2005-0017

M3 - Article

C2 - 16179427

AN - SCOPUS:33646752857

VL - 24

SP - 671

EP - 678

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 3

ER -